

**Dr Joachim Rothe, Chairman**

Joachim Rothe is responsible for Life Science Partner's (LSP) German office in Munich and currently serves on the supervisory boards of BioXell (I), Scion (USA), Affectis (G) and Morphochem (G). Before joining LSP in early 2002, he was a principal at MPM Capital in Cambridge, Mass., and managing director of MPM Capital GmbH based in Munich. In that capacity, Joachim Rothe served on the supervisory boards of Novirio Pharmaceuticals (now: Idenix, of which a majority stake was sold to Novartis in early 2003), Omrix and t. Breeders (now: Viacell). He also served as founding CFO of Idenix. Previously, he was at McKinsey & Company where he worked as an engagement manager on assignments in the chemical and pharmaceutical industries. During his time as a scientist with Hoffmann-La Roche in Basle, Switzerland, Joachim Rothe focused on molecular immunology and contributed to the preclinical development of an important drug candidate. Joachim Rothe holds a masters degree in Biochemistry from the Free University in Berlin, and he earned his PhD degree from the University of Freiburg in Germany, supervised by Georges Köhler (Nobel Prize 1984). He has authored numerous articles in leading scientific publications such as Nature.

**Prof Dr Domenico Valerio, Vice-Chairman**

Domenico Valerio is a scientist and entrepreneur who founded and successfully built the biomedical company Crucell N.V., a NASDAQ- and Euronext listed company with a market capitalisation over € 600 million. He was CEO of Crucell N.V. from its foundation in 1993 until 2004. In 1999 he also founded Galapagos Genomics N.V. as a spin-out from Crucell N.V. Galapagos Genomics N.V. went public on the Euronext stock market in May of 2005. Domenico holds a professorship in Gene Therapy at the Leiden University since 1992. In 1985 Domenico was a 'visiting scientific specialist' at Genentech Inc., San Francisco, USA. He was a post-doctoral fellow at the Salk Institute, San Diego, USA from 1986 to 1987. He received his Master of Science degree in Biology from University of Amsterdam and completed his Ph.D. in Molecular Genetics with Honours at Leiden University in 1986. He published over 100 scientific articles and is an inventor on 80 patents (issued from 11 patent-families).

**Dr Christoph Antz**

Christoph Antz obtained his Ph.D. in physics/structural biology at the Max-Planck-Institute for Medical Research (Heidelberg). He has extensive experience in managing start-up and early-phase biotech companies. In 1998, he co-founded Otogene (Tübingen and Seattle), and after leaving Otogene served as CEO at Abeta (Heidelberg) before joining EMBL Ventures in 2003.

**Alex Martin**

Alex Martin has nearly 20 years of operational experience in the life sciences industry, both in large, world-class organisations as well as in small successful start-up ventures. He is currently Chief Operating Officer of Intercept Pharmaceuticals, a biotechnology company based in New York. Prior to joining Intercept, Mr. Martin served as Chief Business Officer and then Chief Financial Officer at BioXell (BXLN.S), a biopharmaceutical company based in Milan, where he led the company's business development efforts and then took the company public in 2006. Previously, he was Vice President, Global Business Development and Licensing at Novartis Pharma AG, responsible for partnering key assets via co-development and co-commercialisation alliances. His experience also includes four years as Vice President Sales & Marketing at Medscape Inc., a healthcare information company, which went public on the NASDAQ, and nearly 10 years at SmithKline Beecham where he held various positions in finance, marketing and business development. Mr. Martin received his MBA degree from Harvard Business School and his BA degree from Cornell University.

**Prof Dr Wolfgang Wurst, Co-founder**

Wolfgang Wurst is Director of the Institute of Developmental Genetics at the National Research Centre for Environment and Health (GSF) in Munich and Professor at the Technical University Munich. Previous positions: Group leader Molecular Neurogenetics at the Max-Planck-Institute of Psychiatry in Munich and Junior Research Group Leader Department of Mammalian Genetics, GSF Research Center, Neuherberg/ Munich. He studied Biology/Chemistry at the University of Freiburg, Germany, and obtained his PhD at the University of Göttingen, Germany and has longstanding expertise in neural development and molecular neurogenetics. He provides important advice in the establishment of animal models of depression disorders and generates knock-out animals for Affectis' targets. Wolfgang Wurst is coordinating large international consortiums with respect to generating animal models for human diseases.